CY1118327T1 - Χρηση ενος παραγωγου πυραζολιου στην αντιμετωπιση οξεων εξαρσεων χρονιας αποφρακτικης πνευμονοπαθειας - Google Patents

Χρηση ενος παραγωγου πυραζολιου στην αντιμετωπιση οξεων εξαρσεων χρονιας αποφρακτικης πνευμονοπαθειας

Info

Publication number
CY1118327T1
CY1118327T1 CY20161101194T CY161101194T CY1118327T1 CY 1118327 T1 CY1118327 T1 CY 1118327T1 CY 20161101194 T CY20161101194 T CY 20161101194T CY 161101194 T CY161101194 T CY 161101194T CY 1118327 T1 CY1118327 T1 CY 1118327T1
Authority
CY
Cyprus
Prior art keywords
treatment
acute
byu
extremes
production
Prior art date
Application number
CY20161101194T
Other languages
Greek (el)
English (en)
Inventor
Paul Andrew Ford
Original Assignee
Mereo Biopharma 1 Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 1 Limited filed Critical Mereo Biopharma 1 Limited
Publication of CY1118327T1 publication Critical patent/CY1118327T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CY20161101194T 2012-03-20 2016-11-18 Χρηση ενος παραγωγου πυραζολιου στην αντιμετωπιση οξεων εξαρσεων χρονιας αποφρακτικης πνευμονοπαθειας CY1118327T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613187P 2012-03-20 2012-03-20
PCT/EP2013/055730 WO2013139809A1 (en) 2012-03-20 2013-03-19 Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
CY1118327T1 true CY1118327T1 (el) 2017-06-28

Family

ID=47901996

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101194T CY1118327T1 (el) 2012-03-20 2016-11-18 Χρηση ενος παραγωγου πυραζολιου στην αντιμετωπιση οξεων εξαρσεων χρονιας αποφρακτικης πνευμονοπαθειας

Country Status (29)

Country Link
US (2) US9339491B2 (enExample)
EP (1) EP2827860B1 (enExample)
JP (1) JP6091593B2 (enExample)
KR (1) KR101793777B1 (enExample)
CN (1) CN104203234B (enExample)
AU (1) AU2013237503B2 (enExample)
BR (1) BR112014023107B1 (enExample)
CA (1) CA2866108C (enExample)
CL (1) CL2014002471A1 (enExample)
CY (1) CY1118327T1 (enExample)
DK (1) DK2827860T3 (enExample)
ES (1) ES2605942T3 (enExample)
HR (1) HRP20161514T1 (enExample)
HU (1) HUE032004T2 (enExample)
IL (1) IL234537A (enExample)
LT (1) LT2827860T (enExample)
MA (1) MA37455B1 (enExample)
MX (1) MX351996B (enExample)
NZ (1) NZ628392A (enExample)
PH (1) PH12014502107B1 (enExample)
PL (1) PL2827860T3 (enExample)
PT (1) PT2827860T (enExample)
RU (1) RU2625762C2 (enExample)
SG (1) SG11201404941WA (enExample)
SI (1) SI2827860T1 (enExample)
TN (1) TN2014000350A1 (enExample)
TW (1) TWI583381B (enExample)
WO (1) WO2013139809A1 (enExample)
ZA (1) ZA201405871B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600833C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронической обструктивной болезни легких
RU2600822C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронического обструктивного бронхита
WO2017153702A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
US10617674B2 (en) 2016-03-08 2020-04-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
US10331542B2 (en) * 2016-06-23 2019-06-25 International Business Machines Corporation System and method for detecting and alerting unexpected behavior of software applications
GB201612238D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
KR102899004B1 (ko) * 2017-12-11 2025-12-12 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
CN114141383A (zh) * 2021-12-17 2022-03-04 湖南大学 慢阻肺智能护理方法、装置及系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HRP20161514T1 (hr) 2016-12-30
NZ628392A (en) 2016-06-24
TWI583381B (zh) 2017-05-21
US20150031736A1 (en) 2015-01-29
MX351996B (es) 2017-11-06
CA2866108A1 (en) 2013-09-26
IL234537A (en) 2016-09-29
ZA201405871B (en) 2016-01-27
LT2827860T (lt) 2016-12-12
PH12014502107B1 (en) 2019-11-27
SI2827860T1 (sl) 2017-01-31
JP2015510916A (ja) 2015-04-13
MA37455B1 (fr) 2017-03-31
EP2827860B1 (en) 2016-10-26
PT2827860T (pt) 2016-12-20
EP2827860A1 (en) 2015-01-28
PH12014502107A1 (en) 2014-12-10
CA2866108C (en) 2017-03-07
KR101793777B1 (ko) 2017-11-03
HK1200352A1 (en) 2015-08-07
US20160243081A1 (en) 2016-08-25
SG11201404941WA (en) 2014-10-30
TW201343162A (zh) 2013-11-01
KR20140146073A (ko) 2014-12-24
CN104203234B (zh) 2017-06-13
MX2014011291A (es) 2014-10-13
CN104203234A (zh) 2014-12-10
US9339491B2 (en) 2016-05-17
BR112014023107A2 (enExample) 2017-06-20
TN2014000350A1 (en) 2015-12-21
CL2014002471A1 (es) 2015-01-09
AU2013237503A1 (en) 2014-09-25
RU2625762C2 (ru) 2017-07-18
RU2014141893A (ru) 2016-05-10
BR112014023107B1 (pt) 2021-08-10
WO2013139809A1 (en) 2013-09-26
MA37455A1 (fr) 2016-08-31
DK2827860T3 (en) 2016-12-12
ES2605942T3 (es) 2017-03-17
PL2827860T3 (pl) 2017-09-29
HUE032004T2 (en) 2017-08-28
AU2013237503B2 (en) 2016-05-26
JP6091593B2 (ja) 2017-03-08

Similar Documents

Publication Publication Date Title
PH12014502107A1 (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
CY1124007T1 (el) Στοματικες δοσολογικες μορφες παρατεταμενης απελευθερωσης τοφασιτινιμπης
CY1120939T1 (el) Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
MX362485B (es) Nuevos inhibidores de rock.
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
HUE054389T2 (hu) Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására
IL233313A0 (en) Composition of novel carbohydrate drug for treatment of human diseases
AR100663A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
EA201391689A1 (ru) Система доставки лекарственного средства
BR112016007414A2 (pt) método de produção de um comprimido de monocamada, e, comprimido de monocamada
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
EA201992463A1 (ru) Система доставки лекарственного средства
MX382075B (es) Forma de dosis orales de liberación sostenida de tofacitinib.
UA113061C2 (xx) Система доставки лікарського засобу
ITMI20120350A1 (it) Forma di dosaggio per somministrazione orale di principi attivi
TN2014000218A1 (en) Kinase inhibitors